Introduction
After the 1980s, the increase in immunocompromised hosts as a result of the spread of human immunodeficiency virus infection, the increased use of immunosuppressive agents in organ transplantations, aggressive anti-cancer chemotherapy and improved life-saving medical techniques necessitating indwelling catheters has led to a substantial increase in the occurrence of serious fungal infections. 1 Progress in the development of both topical and systemic antifungal agents lagged behind that of antibacterial agents, due in part to the intensive research efforts in the area of antibacterial therapy that began in the 1940s following the large-scale production of penicillin and also to the relatively low incidence of serious fungal infections compared with that of bacterial infections. 2 Recently, new classes of antifungal agents such as the candins, the nikkomycins and the pradimicins-benanomicins have been studied.
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FK463 is a new parenterally administered antifungal drug undergoing phase II clinical trials. It is a semisynthetic derivative of FR901379, a water-soluble cyclic hexapeptide with a fatty acyl side chain similar in structure to the echinocandin class of antifungal agents. The addition of the fatty acid side chain to FR901379 has improved its antifungal potency. FK463 has been shown to have potent fungistatic and fungicidal activity against Candida spp.
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Pharmacokinetic studies in clinical trials suggest that AUC 0-ϱ and C max increase in a dose proportional manner and a mean value of t 1/2 was estimated as 14.7 h. 
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Materials and methods
Compounds
JAC
Antifungal susceptibility assays to determine the MICs of FK463 and other reference antifungal agents were performed by the broth microdilution method according to M27-A guidelines recommended by the National Committee for Clinical Laboratory Standards (NCCLS). 6 The MICs of FK463 and amphotericin B for Candida spp. were defined as the lowest concentrations at which no visible growth was observed, and for fluconazole and itraconazole, the MICs were defined as the lowest concentrations at which a prominent decrease in turbidity was observed.
Minimal fungicidal concentration (MFC) assays
MFCs were determined by the microdilution reference method with an inoculum size of 1.0-2.5 ϫ 10 4 cells/mL of Candida spp. 5 After MIC measurement, the microtitre plates were shaken and a 1 L aliquot was removed from each well of the microtitre plate and transferred to a singlereservoir plate containing Sabouraud dextrose agar. These were incubated for 24-72 h at 35°C. The MFC was defined as the minimum concentration at which no visible growth was observed. This represents killing of Ͼ90% of the original inoculum.
Results and discussion
The MICs and MFCs of FK463 are shown in the Table. The  MIC The management of serious infections due to Candida spp., which are becoming increasingly prevalent, is problematic because of the increasing incidence of non-albicans species and the emergence of non-albicans isolates resistant to both amphotericin B and the newer azoles. 
